ArticleMolecular therapy. Oncology2026
Comparative evaluation of oncolytic viruses reveals opposing preferences for glioblastoma subtypes.
Article in Molecular therapy. Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastoma (GBM) is the most aggressive primary brain tumor in adults characterized by poor long-term survival and frequent tumor recurrence, highlighting the urgent need for novel therapeutic strategies. Oncolytic viruses (OVs) preferentially infect and kill cancer cells while stimulating an antitumor immune response. Oncolytic virotherapies have shown encouraging results in preclinical GBM models and some clinical settings. However, high tumor heterogeneity poses a major obstacle. Only a subset of GBM patients responds well, and improvement in survival is usually limited. It is therefore crucial to better understand determinants of OV effectiveness and to consider multiple OVs. Here, we report a comparative analysis of the oncolytic efficacy of 15 clinically relevant viruses across a diverse panel of 14 heterogeneous patient-derived GBM cell lines. Correlation analysis revealed two clusters of viruses with opposing oncolytic activity profiles and opposing preferences for GBM subtypes. Oncolytic activities correlated with expression levels of interferon-, neurodevelopment-, and extracellular matrix-related gene sets, with inverse correlations observed between the two OV groups. Together, these data reveal that diverse viruses share similar determinants of oncolytic activity. Our findings pave the way toward combinatorial or personalized OV therapies in GBM, where tumor subtype could guide selection of the most effective OV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.